RLMD vs. CLNN, MDCX, ELEV, ANVS, CASI, ATHE, SRZN, INKT, OKYO, and UBX
Should you be buying Relmada Therapeutics stock or one of its competitors? The main competitors of Relmada Therapeutics include Clene (CLNN), Medicus Pharma (MDCX), Elevation Oncology (ELEV), Annovis Bio (ANVS), CASI Pharmaceuticals (CASI), Alterity Therapeutics (ATHE), Surrozen (SRZN), MiNK Therapeutics (INKT), OKYO Pharma (OKYO), and Unity Biotechnology (UBX). These companies are all part of the "pharmaceutical products" industry.
Relmada Therapeutics vs.
Relmada Therapeutics (NASDAQ:RLMD) and Clene (NASDAQ:CLNN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, community ranking, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.
Clene received 56 more outperform votes than Relmada Therapeutics when rated by MarketBeat users. Likewise, 79.35% of users gave Clene an outperform vote while only 37.78% of users gave Relmada Therapeutics an outperform vote.
In the previous week, Clene had 1 more articles in the media than Relmada Therapeutics. MarketBeat recorded 1 mentions for Clene and 0 mentions for Relmada Therapeutics. Clene's average media sentiment score of 1.21 beat Relmada Therapeutics' score of 0.00 indicating that Clene is being referred to more favorably in the news media.
Relmada Therapeutics currently has a consensus price target of $4.25, indicating a potential upside of 1,340.68%. Clene has a consensus price target of $55.25, indicating a potential upside of 1,147.18%. Given Relmada Therapeutics' higher possible upside, research analysts plainly believe Relmada Therapeutics is more favorable than Clene.
Clene has higher revenue and earnings than Relmada Therapeutics. Clene is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.
Relmada Therapeutics has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500. Comparatively, Clene has a beta of 0.24, suggesting that its stock price is 76% less volatile than the S&P 500.
45.2% of Relmada Therapeutics shares are owned by institutional investors. Comparatively, 23.3% of Clene shares are owned by institutional investors. 18.0% of Relmada Therapeutics shares are owned by insiders. Comparatively, 25.1% of Clene shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Relmada Therapeutics has a net margin of 0.00% compared to Clene's net margin of -8,556.77%. Relmada Therapeutics' return on equity of -129.80% beat Clene's return on equity.
Summary
Clene beats Relmada Therapeutics on 11 of the 18 factors compared between the two stocks.
Get Relmada Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Relmada Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:RLMD) was last updated on 2/22/2025 by MarketBeat.com Staff
Free RLMD Stock Alerts